Observational Retrospective Study on Clinical Outcomes of Patients Receiving Benralizumab in Spain.

Inclusion Criteria

• •Adult patients (age ≥18 years)
• •Diagnosis of severe eosinophilic asthma requiring stable treatment of high doses of inhaled corticosteroids and a long-acting agonist β2 ± additional asthma controller.
• •Patients with at least 12-month data available before index date (starting benralizumab treatment)
• •Patients with at least 3-month electronic medical records data available from first benralizumab dose ("index date")
• •Informed consent signed.